Ignite Creation Date:
2024-05-06 @ 5:52 PM
Last Modification Date:
2024-10-26 @ 2:37 PM
Study NCT ID:
NCT05462106
Status:
RECRUITING
Last Update Posted:
2024-05-31
First Post:
2022-07-12
Brief Title:
A Study to Assess the Effects of ACI-24060 in Alzheimers Disease and in Down Syndrome ABATE Study
Sponsor:
AC Immune SA
Organization:
AC Immune SA
Study Overview
Official Title:
A Phase 1b2 Multicenter Adaptive Double-blind Randomized Placebo-controlled Study to Assess the Safety Tolerability Immunogenicity and Pharmacodynamic Effects of ACI-24060 in Subjects With Prodromal Alzheimers Disease and in Adults With Down Syndrome ABATE
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the safety tolerability immunogenicity and pharmacodynamic effects of ACI-24060 in subjects with prodromal Alzheimers disease and in non-demented adults with Down syndrome
Detailed Description:
This phase 1b2 study will be in 2 parts Study Part 1 will involve subjects with prodromal Alzheimers disease Study Part 2 will involve subjects with Down syndrome
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2021-006195-17 | EUDRACT_NUMBER | None | None |
| 2022-500069-29-00 | OTHER | European Union Drug Regulatory Authorities Clinical Trial System | None |